To use a consistent and standardized platform to retrospectively and prospectively study children and young adults with B cell malignancies receiving Immunotherapy, blinatumomab and/or inotuzumab ozogamicin.
Lymphoid Leukemia
To use a consistent and standardized platform to retrospectively and prospectively study children and young adults with B cell malignancies receiving Immunotherapy, blinatumomab and/or inotuzumab ozogamicin.
Outcomes in Pediatric and Young Adult B-Cell Malignancies After Commercially Available Immunotherapy
-
Stanford University, Palo Alto, California, United States, 94305
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
to 26 Years
ALL
No
Stanford University,
Liora Schultz, M.D, PRINCIPAL_INVESTIGATOR, Stanford University
2025-08-30